Weifang Medical University, Weifang 261053, China.
Department of Urology, Weifang People's Hospital, Dezhou 261000, China.
J Healthc Eng. 2022 Feb 7;2022:8446294. doi: 10.1155/2022/8446294. eCollection 2022.
We have proposed an effective mechanism to corroborate the efficacy of microwave ablation (MA) in the treatment of stage I renal clear cell carcinoma in this paper. For this purpose, a total of 96 patients with stage I renal clear cell carcinoma presented in our hospital from May 2018 to January 2021 were randomly divided into CT group ( = 48) and MRI group ( = 48). Patients in both groups were treated with microwave ablation after pathological diagnosis. Patients in the CT group received enhanced CT examination to monitor the therapeutic effect; in contrast, patients in the MRI group received MRI examination to monitor their therapeutic effect. The focus areas before and after tumor microwave ablation were compared between the two groups. The patients were followed up to 1 year after the operation, and the microwave ablation inactivation rates of the two groups were compared according to the postoperative follow-up results. There was no significant difference between CT and MRI in the levels of long and short diameter before and after microwave ablation of renal clear cell carcinoma ( > 0.05). In the CT group, CT examination was performed within 24 hours after microwave ablation treatment, and 44 of 48 ablation lesions showed complete ablation. The remaining 4 lesions showed nodular heterogeneous enhancement in the arterial phase, indicating that the tumor remained. Microwave ablation was performed on the residual lesions during the operation, and then enhanced CT was performed again to show that the lesions were ablated completely. In the MRI group, MRI examination was performed within 24 hours after microwave ablation treatment, and 45 of 48 ablation lesions showed complete ablation. The remaining 3 lesions showed nodular heterogeneous enhancement in the arterial phase, indicating that the tumor remained. Microwave ablation was performed on the residual lesions during the operation, and MRI examination showed that the lesions were ablated completely. The patients were followed up to 1 year after the operation, and the microwave ablation inactivation rate of the two groups was compared according to the postoperative follow-up results as the gold standard. The inactivation rate of microwave ablation in the CT group was 89.58 (43/48). The inactivation rate of microwave ablation in the MRI group was 100.00% (48/48). The inactivation rate of microwave ablation in the MRI group was higher than that in the CT group ( = 5.275, = 0.021).
我们在本文中提出了一种有效的机制来证实微波消融(MA)在治疗 I 期肾透明细胞癌中的疗效。为此,我们从 2018 年 5 月至 2021 年 1 月期间共收治了 96 例 I 期肾透明细胞癌患者,将其随机分为 CT 组(n=48)和 MRI 组(n=48)。两组患者均在病理诊断后接受微波消融治疗。CT 组患者接受增强 CT 检查以监测治疗效果;而 MRI 组患者接受 MRI 检查以监测其治疗效果。比较两组患者肿瘤微波消融前后的焦点区域。术后对患者进行了 1 年的随访,并根据术后随访结果比较了两组患者的微波消融灭活率。肾透明细胞癌微波消融前后长径和短径的 CT 和 MRI 水平差异均无统计学意义(>0.05)。在 CT 组中,在微波消融治疗后 24 小时内进行 CT 检查,48 个消融病灶中有 44 个显示完全消融。其余 4 个病灶在动脉期呈结节状不均匀强化,提示肿瘤残留。在手术中对残留病灶进行微波消融,然后再次进行增强 CT 检查,显示病灶完全消融。在 MRI 组中,在微波消融治疗后 24 小时内进行 MRI 检查,48 个消融病灶中有 45 个显示完全消融。其余 3 个病灶在动脉期呈结节状不均匀强化,提示肿瘤残留。在手术中对残留病灶进行微波消融,MRI 检查显示病灶完全消融。术后对患者进行了 1 年的随访,并根据术后随访结果作为金标准比较了两组患者的微波消融灭活率。CT 组微波消融灭活率为 89.58%(43/48)。MRI 组微波消融灭活率为 100.00%(48/48)。MRI 组的微波消融灭活率高于 CT 组( = 5.275, = 0.021)。